• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Denali Therapeutics Inc. - Common Stock (NQ:DNLI)

    19.93 -0.60 (-2.91%)
    Delayed Quote Updated: 11:06 AM EDT, Oct 2, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 325,870
    Open 20.85
    Bid (Size) 19.93 (200)
    Ask (Size) 19.95 (300)
    Prev. Close 20.53
    Today's Range 19.93 - 20.85
    52wk Range 13.75 - 27.30
    Shares Outstanding 121,640,069
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Klotho Protein Emerges as a Potential Powerhouse In the Next Generation of Longevity Medicine
    EQNX::TICKER_START (OTCQB:AVAI),(NASDAQ:BIOA),(NASDAQ:GERN),(NASDAQ:DNLI) EQNX::TICKER_END 
    Via FinancialNewsMedia
    News headline image
    Denali Therapeutics (DNLI) Q2 2026 Earnings Call Transcript ↗
    AVLAYAH revenue hit $3.6M in first full quarter post-approval. 
    Via The Motley Fool
    Topics Earnings

    Performance

    52-Week Range 27.0% below 52-week high
    19.93
    13.7552W Low 27.3052W High
    1 Week 6.2% below 1-week high
    19.931W Low 21.261W High

    Denali Therapeutics Inc. - Common Stock (DNLI) traded between $13.75 and $27.30 over the past 52 weeks and last traded at $19.93, 27.0% below its 52-week high. Over the past week it ranged between $19.93 and $21.26.

    Past 12 Months
    -2.2%
    -14.3%
    -22.8%
    -3.5%
    +22.5%
    +33.7%
    1W -$0.46
    1M -$3.33
    3M -$5.90
    6M -$0.72
    YTD +$3.66
    1Y +$5.02

    DNLI was +33.7% over the past year, -3.5% over six months, +22.5% year to date, -2.2% in the last week.

    12 Months vs Market
    DNLI
    +33.7%
    DIA
    +10.1%
    SPY
    +15.3%
    QQQ
    +24.6%
    IWM
    +16.7%

    Over the past 12 months DNLI returned +33.7% versus DIA (Dow) +10.1%, SPY (S&P 500) +15.3%, QQQ (Nasdaq 100) +24.6% and IWM (Russell 2000) +16.7%.

    Volume & Liquidity 0.21× 3-mo avg
    Today 325,870 3-mo avg 1.6M
    1W
    1.9M
    1M
    1.8M
    3M
    1.6M
    6M
    1.7M
    YTD
    1.7M
    1Y
    1.7M

    DNLI most recently traded 325,870 shares against a 3-month average daily volume of 1.6M.

    More News

    Read More
    Denali Therapeutics (NASDAQ:DNLI) Shows Perfect Technical Setup for a Breakout ↗
    Via Chartmill
    News headline image
    Denali Therapeutics Q2 Earnings Call Highlights ↗
    Via MarketBeat
    Topics Earnings
    Denali Therapeutics (NASDAQ:DNLI) Drops as Q2 AVLAYAH Revenue Misses Estimates ↗
    Via Chartmill
    News headline image
    Denali Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights
    From Denali Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Denali Therapeutics to Report Second Quarter 2026 Financial Results and Business Highlights on August 6, 2026
    From Denali Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Denali Therapeutics to Give Opening Plenary Address at Alzheimer’s Association International Conference (AAIC) 2026 and Highlight Breakthroughs in Delivering Biologic Therapies Across Blood-Brain Barrier
    From Denali Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Denali Therapeutics Enters Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $195 Million
    From Denali Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Biogen and Denali Therapeutics Provide Update on Phase 2b LUMA Study of BIIB122 (DNL151) in Early-Stage Parkinson’s Disease
    From Denali Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Hedge Fund Wagers $36 Million on Biotech Denali After First FDA Approval ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Denali Therapeutics Says AVLAYAH Launch Ahead of Expectations After Hunter Syndrome Approval ↗
    Via MarketBeat
    News headline image
    Denali Therapeutics Reports First Quarter 2026 Financial Results and Business Highlights
    From Denali Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Privium Fund Opens $5.07 Million Denali Stake Ahead of FDA Drug Approval ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    BioMedNewsBreaks — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Featured in BioMedWire Editorial Highlighting Biotech’s Shift Toward Science-Driven Asset Valuation
    Via Investor Brand Network
    Topics Artificial Intelligence
    News headline image
    When Science Becomes an Asset: How Advancing Drug Pipelines Are Driving Real-Time Valuation in Biotech
    From BioMedWire
    Via GlobeNewswire
    News headline image
    Denali Therapeutics Regains Full Rights to Investigational Therapy DNL593 (PTV:PGRN) for GRN-related Frontotemporal Dementia (FTD-GRN)
    From Denali Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Ultragenyx Vaults Toward Commercialization as FDA Accepts Landmark Gene Therapy BLA
    Via MarketMinute
    Topics Intellectual Property Lawsuit
    News headline image
    The Brain Barrier Broken: Inside Denali Therapeutics’ Landmark FDA Approval of AVLAYAH
    Via Finterra
    Topics Economy Initial Public Offering
    News headline image
    Denali Therapeutics Announces U.S. FDA Approval of AVLAYAH™ (tividenofusp alfa-eknm) for Treatment of Hunter Syndrome (MPS II)
    From Denali Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Denali Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights
    From Denali Therapeutics Inc.
    Via GlobeNewswire
    Drug-Delivery Breakthroughs, Cross-Indication Research Accelerate New Momentum in CNS and Oncology Development
    Via Investor Brand Network
    Topics Intellectual Property
    News headline image
    Drug-Delivery Breakthroughs, Cross-Indication Research Accelerate New Momentum in CNS and Oncology Development
    From BioMedWire
    Via GlobeNewswire
    News headline image
    Biogen (BIIB) Q4 Earnings Preview: The "New Biogen" Emerges as Alzheimer's and Rare Disease Pipelines Take Center Stage
    Via MarketMinute
    Topics Intellectual Property
    News headline image
    Denali Therapeutics Presents Enzyme TransportVehicle™ Progress Across Three Clinical Programs for Treatment of Lysosomal Storage Disorders at 2026 WORLDSymposium™
    From Denali Therapeutics Inc.
    Via GlobeNewswire

    Frequently Asked Questions

    Is Denali Therapeutics Inc. - Common Stock publicly traded?
    Yes, Denali Therapeutics Inc. - Common Stock is publicly traded.
    What exchange does Denali Therapeutics Inc. - Common Stock trade on?
    Denali Therapeutics Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Denali Therapeutics Inc. - Common Stock?
    The ticker symbol for Denali Therapeutics Inc. - Common Stock is DNLI on the Nasdaq Stock Market
    What is the current price of Denali Therapeutics Inc. - Common Stock?
    The current price of Denali Therapeutics Inc. - Common Stock is 19.93
    When was Denali Therapeutics Inc. - Common Stock last traded?
    The last trade of Denali Therapeutics Inc. - Common Stock was at 10/02/26 11:06 AM ET
    What is the market capitalization of Denali Therapeutics Inc. - Common Stock?
    The market capitalization of Denali Therapeutics Inc. - Common Stock is 2.42B
    How many shares of Denali Therapeutics Inc. - Common Stock are outstanding?
    Denali Therapeutics Inc. - Common Stock has 2B shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.